PDF(Pubmed)
Abstract：
Background: Treatment for refractory or relapsed primary CNS lymphoma (r/r PCNSL) is challenging. Salvage whole-brain radiation therapy (WBRT) is an option but has a short duration of disease control, so additional treatment modalities are warranted. Case: A 75-year-old female with r/r PCNSL who had multiple progressions after multiple lines of treatment underwent salvage WBRT. The patient received ibrutinib, a Bruton\'s tyrosine kinase inhibitor, as maintenance therapy for 18 months following WBRT with the intention of increasing survival duration after salvage WBRT. She survived 81 months from diagnosis, including 57 months after completion of WBRT. Conclusion: This case presentation describes the experience of using ibrutinib as maintenance therapy in treating r/r PCNSL after salvage WBRT.
Treatment for refractory or relapsed primary CNS lymphoma (r/r PCNSL) is difficult. Salvage whole-brain radiation therapy (WBRT) is one treatment choice, but the effects do not last very long. Therefore, additional treatment regimens are needed. The authors report a 75-year-old female with r/r PCNSL who had several progressions after multiple lines of treatment and underwent salvage WBRT. Following WBRT, the patient received ibrutinib, a Bruton\'s tyrosine kinase inhibitor, as maintenance therapy for 18 months to increase the duration of survival after salvage WBRT. She survived 81 months from diagnosis, including 57 months after completion of WBRT. This case reflects the experience of using ibrutinib as maintenance therapy in treating r/r PCNSL after salvage WBRT.
Treatment for refractory or relapsed primary CNS lymphoma (r/r PCNSL) is difficult. Salvage whole-brain radiation therapy (WBRT) is one treatment choice, but the effects do not last very long. Therefore, additional treatment regimens are needed. The authors report a 75-year-old female with r/r PCNSL who had several progressions after multiple lines of treatment and underwent salvage WBRT. Following WBRT, the patient received ibrutinib, a Bruton\'s tyrosine kinase inhibitor, as maintenance therapy for 18 months to increase the duration of survival after salvage WBRT. She survived 81 months from diagnosis, including 57 months after completion of WBRT. This case reflects the experience of using ibrutinib as maintenance therapy in treating r/r PCNSL after salvage WBRT.
摘要：
背景：难治性或复发性原发性中枢神经系统淋巴瘤（r/rPCNSL）的治疗具有挑战性。抢救全脑放射治疗（WBRT）是一种选择，但疾病控制持续时间短，因此需要额外的治疗方式.病例：一名75岁的r/rPCNSL女性，在多行治疗后多次进展，接受了挽救性WBRT。病人接受了ibrutinib,布鲁顿酪氨酸激酶抑制剂，作为WBRT后18个月的维持治疗，目的是增加抢救WBRT后的生存期。她确诊后存活了81个月,包括WBRT完成后的57个月。结论：本病例介绍了挽救WBRT后使用依鲁替尼作为维持治疗r/rPCNSL的经验。
难治性或复发性原发性CNS淋巴瘤(r/rPCNSL)的治疗是困难的。抢救全脑放射治疗（WBRT）是一种治疗选择，但是效果不会持续很长时间。因此,需要额外的治疗方案.作者报告了一名患有r/rPCNSL的75岁女性，经过多行治疗后出现了一些进展，并接受了挽救性WBRT。WBRT之后,病人接受了ibrutinib,布鲁顿酪氨酸激酶抑制剂，作为18个月的维持治疗，以增加抢救后WBRT的生存期。她确诊后存活了81个月,包括WBRT完成后的57个月。该病例反映了在抢救WBRT后使用依鲁替尼作为维持治疗r/rPCNSL的经验。
难治性或复发性原发性CNS淋巴瘤(r/rPCNSL)的治疗是困难的。抢救全脑放射治疗（WBRT）是一种治疗选择，但是效果不会持续很长时间。因此,需要额外的治疗方案.作者报告了一名患有r/rPCNSL的75岁女性，经过多行治疗后出现了一些进展，并接受了挽救性WBRT。WBRT之后,病人接受了ibrutinib,布鲁顿酪氨酸激酶抑制剂，作为18个月的维持治疗，以增加抢救后WBRT的生存期。她确诊后存活了81个月,包括WBRT完成后的57个月。该病例反映了在抢救WBRT后使用依鲁替尼作为维持治疗r/rPCNSL的经验。
